| Bioactivity | Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke[1][2]. |
| Invitro | Glenzocimab (0-100000 ng/mL) 抑制 GPVI-Fc 与固定在微量滴定板上的胶原蛋白结合，IC50 为 1.37 μg/mL[2]。 |
| In Vivo | Glenzocimab (1-8 mg/kg; i.v.) 抑制食蟹猴中胶原诱导的血小板聚集[2]。 Animal Model: |
| Name | Glenzocimab |
| CAS | 2101829-58-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wichaiyo S, et al. Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke. Stroke. 2022 Nov;53(11):3506-3513. [2]. Lebozec K, et al. Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks. MAbs. 2017 Aug/Sep;9(6):945-958. |